Related Experiment Video
Updated: Apr 26, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.6K
Recent clinical trials in lupus nephritis
1Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Building 10CRC, Room 4-1339, 10 Center Drive, Bethesda, MD 20892, USA.
Rheumatic Diseases Clinics of North America
|July 19, 2014
Summary
Low-dose cyclophosphamide and mycophenolate mofetil show promise for lupus nephritis induction. Mycophenolate mofetil may be a viable maintenance option, potentially more effective in certain ethnic groups.
Area of Science:
- Nephrology
- Immunology
- Rheumatology
Background:
- Proliferative lupus nephritis requires effective immunosuppressive therapy.
- Optimizing induction and maintenance regimens is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of low-dose intravenous cyclophosphamide and mycophenolate mofetil in lupus nephritis.
- To compare maintenance treatment options including mycophenolate mofetil, quarterly cyclophosphamide, and azathioprine.
Main Methods:
- Comparative clinical trials assessing induction and maintenance therapies for proliferative lupus nephritis.
- Analysis of treatment responses based on drug regimens and patient ethnicity.
Main Results:
- Low-dose intravenous cyclophosphamide and mycophenolate mofetil demonstrated efficacy in induction therapy compared to standard-dose cyclophosphamide.
- Mycophenolate mofetil showed comparable efficacy to quarterly cyclophosphamide and superior efficacy to azathioprine for maintenance.
- Potential for greater efficacy of mycophenolate mofetil in Black and Hispanic patients.
- Rituximab was not effective as an adjunct therapy with mycophenolate mofetil during induction.
Conclusions:
- Low-dose cyclophosphamide and mycophenolate mofetil represent effective induction options for lupus nephritis.
- Mycophenolate mofetil is a promising maintenance therapy, with potential ethnic-specific benefits.
- Further research into personalized treatment strategies for lupus nephritis is warranted.
